Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 15/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056298 | 1.00 | PTGFR (0.54) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3056297 | 1.00 | PTGFR (0.54) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3048487 | 0.93 | PTGFR (0.53) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3048486 | 0.93 | PTGFR (0.53) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3048480 | 0.93 | PTGFR (0.53) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3043724 | 0.91 | PTGFR (0.65) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3043720 | 0.91 | PTGFR (0.65) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3043727 | 0.91 | PTGFR (0.65) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3045453 | 0.89 | PTGFR (0.67) | PTGFRPTGER3ABCC4ABCB11MAPT | |
| SCHEMBL3045460 | 0.89 | PTGFR (0.67) | PTGFRPTGER3ABCC4ABCB11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | LIPKIN PAMELA | 2010-03-25 | — | — | US | claimed |
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | LIPKIN PAMELA | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | PTGER1, PGF, PTGER2 | PTGFR 6/4885PTGER3 9/4885ABCC4 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.